Efficacy of RAD001/everolimus in Autism and NeuroPsychological deficits in children with TSC (RAPIT-trial)

Trial Profile

Efficacy of RAD001/everolimus in Autism and NeuroPsychological deficits in children with TSC (RAPIT-trial)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 May 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Tuberous sclerosis
  • Focus Therapeutic Use
  • Acronyms RAPIT
  • Most Recent Events

    • 20 Nov 2012 Planned end date changed from 14 Mar 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record. 992332
    • 20 Nov 2012 New source identified and integrated (ClinicalTrials.gov; NCT01730209).
    • 18 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top